Aridis Pharmaceuticals Inc (NASDAQ:ARDS)
| 1.92 BATS BZX Real-Time Price As of 1:18pm ET |  +0.30 / +18.52%Today’s Change | 1.13 Today|||52-Week Range 8.47 | -17.60% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $22.3M |
Company Description
Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-101, AR-501, AR-712, AR-701, AR-401, AR-105 and AR-201. The company was founded by Eric J. Patzer and Vu L. Truong in 2003 and is headquartered in Los Gatos, CA.
Contact Information
Aridis Pharmaceuticals, Inc. 983 University Avenue Los Gatos California 95032 |
Employees
Shareholders
| Mutual fund holders | 7.34% |
| Other institutional | 11.47% |
| Individual stakeholders | 10.29% |
Top Executives
| Vu L. Truong | Director, Chief Executive & Scientific Officer |
| Fred Kurland | Chief Financial & Accounting Officer |
| Hasan Jafri | Chief Medical Officer |
| Steven M. Chamow | Vice President-Research & Development |
| Lisa Sher | Head-Investor & Public Relations |
